What is in silico drug design? And what role is it playing in drug discovery? How is cloud computing removing the limitations for in silico screening? We will learn those answers and more in this week’s episode with Dr. John Bruning, a Senior Lecturer in the School of Biological Sciences at the University of Adelaide in Southern Australia, where he also founded the University’s laboratory of protein crystallography. Dr. Bruning is also an Oracle for Research Fellow and was named a finalist for the 2022 Oracle Excellence Award in the Eureka Award category. Dr. Bruning received his Bachelor of Science from Texas A&M University and his PhD from Rice University. He has completed two post-doctoral research positions in structure guided drug design at the Scripps Research Institute and the Texas A&M Health Science Center in the Houston Medical Center. His research has been cited in numerous peer-reviewed journals. You can learn more about Dr. Bruning and his work here: https://researchers.adelaide.edu.au/profile/john.bruning Learn more about Oracle for Research: http://www.oracle.com/research